Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 32572158
Du R, et al. (2020) SDCBP/MDA-9/syntenin phosphorylation by AURKA promotes esophageal squamous cell carcinoma progression through the EGFR-PI3K-Akt signaling pathway. Oncogene 32572158
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S131-p - syntenin (human)
Modsite: kIGLRLKsIDNGIFV SwissProt Entrez-Gene
Orthologous residues
syntenin (human): S131‑p, syntenin iso2 (human): S130‑p, syntenin (mouse): S132‑p, syntenin (rat): S133‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  esophageal cancer, esophageal carcinoma
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), Kyse410 (esophageal)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AurA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE AurA (human) siRNA inhibition of enzyme, transfection of wild-type enzyme, modification site within consensus motif, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease siRNA for AurA decreases phosphorylation
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein stabilization
Effect of modification (process):  carcinogenesis, induced, signaling pathway regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
FAK (human) Induces co-immunoprecipitation
Src (human) Induces co-immunoprecipitation
EGFR (human) Induces intracellular localization co-immunoprecipitation
Comments:  Inhibits ubiquitination; AURKA-SDCBP-EGFR-PI3K-AKT pathway
Associated Diseases
Diseases Alterations Comments
esophageal cancer increased

T200-p - syntenin (human)
Modsite: RPFERTItMHKDSTG SwissProt Entrez-Gene
Orthologous residues
syntenin (human): T200‑p, syntenin iso2 (human): T199‑p, syntenin (mouse): T201‑p, syntenin (rat): T202‑p
Characterization
Methods used to characterize site in vivo mutation of modification site, western blotting
Disease tissue studied:  esophageal cancer, esophageal carcinoma
Relevant cell lines - cell types - tissues:  HEK293T (epithelial), Kyse410 (esophageal)
Cellular systems studied:  cell lines
Species studied:  human
Enzymes shown to modify site in vitro
Type Enzyme
KINASE AurA (human)
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE AurA (human) siRNA inhibition of enzyme, transfection of wild-type enzyme, modification site within consensus motif, co-immunoprecipitation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
siRNA decrease siRNA for AurA decreases phosphorylation
Downstream Regulation
Effect of modification (function):  molecular association, regulation, protein stabilization
Effect of modification (process):  carcinogenesis, induced, signaling pathway regulation
Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
EGFR (human) Induces intracellular localization co-immunoprecipitation
Src (human) Induces co-immunoprecipitation
FAK (human) Induces co-immunoprecipitation
Comments:  Inhibits ubiquitination; AURKA-SDCBP-EGFR-PI3K-AKT pathway
Associated Diseases
Diseases Alterations Comments
esophageal cancer increased